Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.

You may also be interested in...



Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel

SEOUL - South Korean local pharmas Hanlim Pharm, Daewoong Pharmaceutical and Pacific Pharma are gearing up to sell an incrementally modified version of Actonel (risendronate), which was originally developed by Sanofi-Aventis and has been sold in Korea by local firm Handok Pharmaceuticals

Actonel Approved For Male Osteoporosis Indication

The approval brings the Proctor & Gamble/Sanofi-Aventis product in line with competitors.

Actonel Approved For Male Osteoporosis Indication

The approval brings the Proctor & Gamble/Sanofi-Aventis product in line with competitors.

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel